Affordable Access

Access to the full text

Thermogel Delivers Oxaliplatin and Alendronate in situ for Synergistic Osteosarcoma Therapy

Authors
  • Sun, Yifu1
  • Li, Ke2
  • Li, Chen1
  • Zhang, Ying3
  • Zhao, Duoyi2
  • 1 Department of Orthopedics, The Second Hospital of Jilin University, Changchun , (China)
  • 2 Department of Orthopedics, The Fourth Affiliated Hospital of China Medical University, Shenyang , (China)
  • 3 Department of Orthopedics, Zhongshan Hospital Affiliated to Xiamen University, Xiamen , (China)
Type
Published Article
Journal
Frontiers in Bioengineering and Biotechnology
Publisher
Frontiers Media SA
Publication Date
Sep 15, 2020
Volume
8
Identifiers
DOI: 10.3389/fbioe.2020.573962
Source
Frontiers
Keywords
Disciplines
  • Bioengineering and Biotechnology
  • Original Research
License
Green

Abstract

The therapeutic effect of osteosarcoma (OS) has not made extraordinary progress in the past few decades. Oxaliplatin (OXA) is a widely used clinical anti-tumor drug. Recent studies have shown that OXA can trigger anti-tumor immunity by inducing immunogenic death (ICD). Alendronate (ALN) has been used to threaten the skeletal system tumors because of the unique bone affinity and the ability to inhibit bone destruction. In this study, we co-loaded OXA and ALN on mPEG45–PLV19 thermo-sensitive hydrogel to perform in situ treatment on the mouse OS model. Slowly released OXA can induce immunogenic death of tumor cells. At the same time, thermo-sensitive hydrogels can induce the accumulation of cytotoxic T lymphocytes. Besides, ALN could synergistically diminish tumors and prevent bone destruction. This system could synergistically inhibit the progression of OS and lung metastasis and has no toxicity to various organs throughout the body.

Report this publication

Statistics

Seen <100 times